id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-256556-1zea3wa1	Lou, Yan	Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial	2020-10-25		.txt	text/plain	4228	225	50	The percentage of patients who turned viral negative after 14-day treatment was 70%, 77%, and 100% in the baloxavir marboxil, favipiravir, and control group respectively, with the medians of time from randomization to clinical improvement was 14, 14 and 15 days, respectively. Then, an exploratory single center, open-label, randomized, controlled trial was conducted to evaluate the efficacy and safety of adding baloxavir marboxil or favipiravir to the current standard antiviral treatment in patients confirmed as COVID-19 who are still positive for the SARS-CoV-2 (ChiCTR2000029544). This trial was an exploratory single center, open-label, randomized, controlled trial to evaluate the efficacy and safety of adding baloxavir marboxil or favipiravir to the current standard antiviral treatment in patients confirmed as COVID-19 who are still positive for the SARS-CoV-2 (ChiCTR2000029544). The activity against SARS-CoV-2 was tested in vitro for the antiviral drugs used in this trial, including arbidol, ritonavir, lopinavir, darunavir, baloxavir acid, and favipiravir.	./cache/cord-256556-1zea3wa1.txt	./txt/cord-256556-1zea3wa1.txt